Latest news

• Roche wins early use RA approval for RoActemra in Europe

  Roche wins early use RA approval for RoActemra in Europe. Adds to existing indications in arthritis and Castleman’ s disease. ... The study showed patients on the combination experienced a significantly greater improvement in disease activity (DAS28

• EC approves Janssen rare blood disorder drug

  EC approves Janssen rare blood disorder drug. Sylvant available to treat multicentric Castleman's disease. ... Janssen's Sylvant this week became the first drug approved in Europe to treat the rare blood disorder multicentric Castleman's disease (MCD).

• FDA approves Janssen drug for rare Castleman’s disease

  FDA approves Janssen drug for rare Castleman’ s disease. Sylvant approved to treat lymphoma-like condition. ... It is also designated an orphan drug due to the rarity of multicentric Castleman's disease.

• EMA backs Janssen rare disease drug for approval

  EMA backs Janssen rare disease drug for approval. Castleman's disease treatment Sylvant wins CHMP recommendation. ... J&J subsidiary Janssen-Cilag's Castleman's disease treatment Sylvant (situximab) has been recommended for approval in Europe.

• J&J positive about pipeline

  The stable of products that are nearing readiness to be filed with regulators in the US and EU includes bapineuzumab IV for Alzheimer's disease, which the company acquired from Elan ... Also on the list are fulranumab for osteoarthritis pain; siltuximab